Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vaporised medicinal cannabis for cancer-related anorexia
ACTRN12616000516482Phase 2Terminated
- Sponsor
- University of New South Wales
- Start
- Feb 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bedrobinol in anorexia nervosa (AN), sponsored by University of New South Wales. Primary endpoints: Plasma concentrations of delta-9-tetrahydrocannabinol and Appetite numerical rating scale. Started Feb 2017; status: terminated.
02
Drugs
bedrobinol
03
Conditions
anorexia nervosa (AN)
Beyond the preview
Go deeper on ACTRN12616000516482.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12616000516482.